|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1009 Stirling Road |
Address2 |
|
| City | Silver Spring |
State | MD |
Zip Code | 20901 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Baltimore |
State | MD |
Zip Code | 21202 |
Country | USA |
|
5. Senate ID# 401104766-12
|
||||||||
|
6. House ID# 439480001
|
||||||||
| TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Shawn Brown |
Date | 5/25/2022 5:11:52 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has a commercial headquarters in Baltimore, Maryland, and a Corporate Headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer, providing about 400 jobs in 3 states. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market in the US.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
None
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
Esq. |
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DIS
16. Specific lobbying issues
None.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Brown |
|
VP of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Ltd. based in Mumbai, India. LPI maintains a sales headquarters in Baltimore Maryland, and national headquarters in Naples, Florida. Lupin supports about 700 jobs across 4 states.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |